| Literature DB >> 34109176 |
Andrei Turkin1, Oksana Tuchina1, Friederike Klempin2.
Abstract
Microglia are the resident immune cells of the adult brain that become activated in response to pathogen- or damage-associated stimuli. The acute inflammatory response to injury, stress, or infection comprises the release of cytokines and phagocytosis of damaged cells. Accumulating evidence indicates chronic microglia-mediated inflammation in diseases of the central nervous system, most notably neurodegenerative disorders, that is associated with disease progression. To understand microglia function in pathology, knowledge of microglia communication with their surroundings during normal state and the release of neurotrophins and growth factors in order to maintain homeostasis of neural circuits is of importance. Recent evidence shows that microglia interact with serotonin, the neurotransmitter crucially involved in adult neurogenesis, and known for its role in antidepressant action. In this chapter, we illustrate how microglia contribute to neuroplasticity of the hippocampus and interact with local factors, e.g., BDNF, and external stimuli that promote neurogenesis. We summarize the recent findings on the role of various receptors in microglia-mediated neurotransmission and particularly focus on microglia's response to serotonin signaling. We review microglia function in neuroinflammation and neurodegeneration and discuss their novel role in antidepressant mechanisms. This synopsis sheds light on microglia in healthy brain and pathology that involves serotonin and may be a potential therapeutic model by which microglia play a crucial role in the maintenance of mood.Entities:
Keywords: BDNF; fluoxetine; hippocampus; microglia; neuroinflammation; serotonin
Year: 2021 PMID: 34109176 PMCID: PMC8182052 DOI: 10.3389/fcell.2021.665739
Source DB: PubMed Journal: Front Cell Dev Biol ISSN: 2296-634X
Summary of recent findings on microglia function in neuroplasticity and neuro-inflammation in the hippocampus, with focus on serotonin and antidepressant action.
| Microglia represent a diverse and vigilant phenotype with high numbers in the dentate gyrus | ||
| 5-HT, 5-HTR | Microglia interact with local neurotransmitters and hormones | |
| Microglia contribute to adult neurogenesis | ||
| TNF-α, ATP, glutamate | Synapse plasticity | |
| ATP, BDNF | ATP-P2X4 drives BDNF release from microglia | |
| BDNF | Microglia-mediated synaptogenesis | |
| BDNF | In neuroinflammation, microglia-mediated BDNF signaling causes synaptic disinhibition | |
| Microglia phagocytosis of apoptotic newborn cells in the dentate gyrus through the phagocytosis secretome | ||
| Tph2, Iba-1 | Running-induced microgliosis in wild-type hippocampus that is further enhanced in mice lacking brain serotonin | |
| B2R, Iba-1 | Running-induced microgliosis in hippocampus of bradykinin B2 receptor knockout mice | |
| Iba-1 | Physical exercise increases newborn microglia numbers in cortex, but decreases the amount in adult amygdala | |
| Iba-1 | Long-term ENR enhances microgliosis in adult hippocampus and amygdala, hypertrophied and ramified microglia morphology | |
| Iba-1 | Increased microglia complexity in CA3, reduced diversity in molecular layer in ENR | |
| BDNF | Physical exercise strongly induces BDNF release in rodents, and humans | |
| BDNF | Skeletal muscle releases cathepsin B during running in monkeys that affects BDNF levels in the brain | |
| Interplay of the endocrine, immune and limbic systems during stress | ||
| Senescent myeloid cells decrease process motility and chemotaxis | ||
| TNF-α, IL-1, IL-18 in AD | Enhanced release of pro-inflammatory cytokines in disease progression | |
| AD | Dysfunctional microglia in disease progression | |
| IL-1β, IL-6 in AD, major depression | Enhanced peripheral levels in patients | |
| BDNF in AD | In AD inflammation, release of BDNF by microglia in close proximity to plaques | |
| TNF-α, glutamate in AD | b-amyloid-induced microglia-mediated cell death | |
| BDNF, IL-10 | BDNF promotes IL-10 release in multiple sclerosis | |
| Cytokines | Distinctive cytokines acting on cell proliferation and differentiation | |
| IL-10 | Anti-inflammatory; promotes synaptic plasticity and long-term potentiation | |
| IL-10 IL-6 | Potent suppression of pro-inflammation and robust support of adult neurogenesis | |
| Fractalkine/CX3CR1 | Prominent chemokine regulator of neuron–microglia communication in the postnatal and adult dentate gyrus; important for synaptic pruning | |
| Fractalkine/CX3CR1 in AD, chronic stress | Deficiency results in microglia-induced pro-inflammation and impaired neurogenesis | |
| LPS, BrdU and neuronal markers | Dose- and time-dependent effects on cell proliferation, survival and neuronal fate in the adult dentate gyrus, | |
| LPS, BrdU | Negative correlation of activated microglia-newborn cells | |
| LPS BDNF-TrkB | (LPS-induced) microglia activation, transformation can be reduced by BDNF or TrkB agonist treatment; BDNF sustains Ca2+ elevation | |
| 5-HT, Tph2, VMAT, SERT, Iba-1, CD11b | Serotonin depletion increases microgliosis in dorsal raphe, and subcommissural organ | |
| LPS, 5-HT | Transient increased microglia numbers and a depressive-like phenotype upon chronic LPS | |
| LPS, Omega-3, 5-HT | Fish oil reverses depression-like behavior, increases serotonin in the hippocampus | |
| 5-HT | Microglial processes in close proximity to serotonergic axons in the adult hippocampus | |
| 5-HT, Ca2+ | Transient enhanced Ca2+ signaling in response to serotonin | |
| 5-HT2A/B, 5-HT4, Ca2+ | Serotonin stimulates secretion of exosomes from microglia cells | |
| 5-HTR, 5-HT2B, LPS, TNF-α, IL-6 | Serotonin promotes microglia-induced targeted motility, but attenuates phagocytosis activity | |
| 5-HT2B | Serotonin–microglia neurotransmission in development | |
| In the lack of | ||
| 5-HT7 | Microglia-mediated serotonin neurotransmission to maintaining anti-inflammatory state | |
| 5-HT7 | Present on human microglial MC-3 cells | |
| 5-HT7, IL-6, AD | Promotes synaptogenesis and inflammatory priming | |
| FLX | Diminished microglia activation in ischemia | |
| FLX, TNF-α, IL-6 | Reduction in TNF-α and IL-6 secretion, | |
| FLX, TNF-α, IL-1β | Fluoxetine-induced neuroprotection in the dentate gyrus following kainate-mediated neuronal cell death | |
| FLX, TNF-α, IL-1β | Reduction in the release of pro-inflammatory cytokines, and glutamate, | |
| FLX, TNF-α, IL-1β Iba-1, CD11b | Treatment on microglia activation and cytokine release differs depending on environmental conditions | |
| FLX, SERT, CD11b | Inhibition of SERT increases CD11b expression accompanied by loss of dopaminergic neurons | |
| FLX | Attenuates symptoms in COVID-19 patients | |
FIGURE 1Illustration of microglia function in neuroplasticity of the hippocampus. In close proximity to precursor cells and neurons in the dentate gyrus, resting microglia control the neuronal cell pool by removal of apoptotic progenitor cells and synapse pruning, regulate synaptic plasticity and neural network excitability via ATP, and the release of TNF-α and BDNF, and respond to serotonin (5-HT) neurotransmission. Microglia express 5-HT receptors, most prominently 5-HT2B in response to serotonin, and CX3CR1 in response to neuronal fractalkine/CX3CL1 signaling that allows surveillance of the niche, and communication with neurons to maintain homeostasis. In particular, serotonin neurotransmission can direct microglia function toward neuroprotection or permit the response to inflammation. Dense tracts of serotonergic fibers terminate in the hippocampus. Upon receptor binding, 5-HT2B, coupled to Gαq/G11 protein, activates phospholipase C (PLC), which hydrolyzes phosphatidylinositol-4,5-bisphosphonate (PIP2), and mediates cellular effects through increasing levels of inositol triphosphate (IP3) and diacylglycerol (DAG). IP3 promotes Ca2+ excretion from endoplasmic reticulum, which activates Iba-1 involved in motility and phagocytosis activity of microglia, and is affected by 5-HT2B. IP3-induced Ca2+ release can also stimulate phospholipase C (PLC) (likewise via DAG), activating nuclear factor kappa beta (NF-kB) and in turn controls the expression of pro-inflammatory genes, e.g., TNF-α, IL-1β, and IL-6. Activated by 5-HT4 and 5-HT7 coupled to Gαs, the enzyme adenylate cyclase (AC) synthesizes the second messenger elevating cyclic AMP (cAMP) from ATP that activates protein kinase A (PKA); cAMP response element-binding protein (CREB) then controls transcription of genes involved in the anti-inflammatory response, BDNF or IL-10, exerting effects through their receptors, TrkB and IL-10R, located on precursor cells (TrkB) and neurons. 5-HT5A interactions with Gαi protein inhibit AC and downstream cascades. Upon harmful stimuli, microglia secrete pro-inflammatory cytokines, TNF-α, IL-1β, and IL-6, and actively remove cell debris. In prolonged neuroinflammation, microglia–neuron communication is altered, leading to neurodegeneration and cognitive deficits. In response to SSRIs, targeting SERT and presynaptic 5-HT1A auto-receptors on serotonergic neurons, 5-HT availability is enhanced in the synaptic cleft, which may also modulate BDNF levels. Increased release of pro-inflammatory cytokines may be counter-balanced by increased 5-HT levels upon SERT inhibition through fluoxetine—having anti-inflammatory properties. 5-HT, 5-hydroxytryptamine; BDNF, brain-derived neurotrophic factor and its receptor TrkB (tropomyosin-related kinase receptor B); Iba-1, ionized calcium binding adaptor molecule 1; SERT, serotonin transporter; TNF, tumor necrosis factor; VMAT2, vesicular monoamine transporter 2. BioRender was used to build the image.